Furthermore, pharmacological blockade of A2AR in vivo by antagonist SCH58261 repressed the tumor growth, inducing a reduction of CD4+ Foxp3+ Tregs and an enhanced anti-tumor response of CD8+ T cells. Here, FOXP3 is linked to neoplasm.